RE:RE:RE:RE:RE:RE:Any news?
Maybe speculator. But the lowly chart says that this stock has never been the victim of optimistic speculation like 101% of other biotechs in a similar position with the FDA. Maybe people are adding 2 + 2 and realizing that there is something here. there are single swing P2 biotechs on my tracking list worth 15 - 20 times Telesta this morning. Maybe they aren't saddled with lead bags like wholly owned/ready to roll manufacturing or stuck with major European partners like Telesta, but 15 - 20 times. C'mon!